Prolia® (denosumab) Arriving Worldwide for the treatment of postmenopausal osteoporosis — ...
Klikken: 147, website toegevoegd: Mar 24, 2014
|
|
| |||||||||||||||||
Prolia® (denosumab), the first and only approved RANK Ligand inhibitor, has filed for approval worldwide for the treatment of postmenopausal osteoporosis.